X4 Pharmaceuticals (NASDAQ:XFOR) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) released its quarterly earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03), Zacks reports. The company had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.07 million.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $0.27 on Thursday. The business’s fifty day moving average is $0.44 and its 200 day moving average is $0.53. X4 Pharmaceuticals has a 52-week low of $0.24 and a 52-week high of $1.60. The firm has a market cap of $46.78 million, a price-to-earnings ratio of -2.99 and a beta of 0.39. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

Wall Street Analysts Forecast Growth

XFOR has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a report on Friday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a report on Wednesday.

Insider Transactions at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares in the company, valued at $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 202,663 shares of company stock valued at $91,198. 1.62% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE lifted its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 133,502 shares of the company’s stock after acquiring an additional 22,485 shares during the period. Bank of America Corp DE owned approximately 0.08% of X4 Pharmaceuticals worth $98,000 as of its most recent SEC filing. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.